Turna Ray

Before drawing definitive conclusions, however, researchers should look at ancestry instead of self-reported race, consider social determinants of health, and improve diversity in trials, experts said.

The company is under financial pressure due to recent regulatory difficulties with Rubraca, the company's only marketed drug.

The company, infamous and long derided in the genetic testing community for refusing to share BRCA1/2 variants, has decided to change its stance as part of a "strategic transformation."

However, the strong performance of several personalized cancer medicines, such as Tecentriq and Phesgo, helped soften the negative impact.

An oncologist doesn't alert a young woman that a TP53 variant she inherited has been upgraded to pathogenic classification, which delays recommended cancer screening and cascade testing.

If the Center for Genomic Interpretation's in silico quality assessment catches on with payors, some labs are sure to push back or propose data sharing as an alternative.

The payor wants to see data beyond what is required through CLIA, and recommends labs use the Center for Genomic Interpretation to gauge how well tests detect and interpret variants.

Oncologists at ESMO said they're eager to see mature data on the drug's impact on duration of response and overall survival in patients with FGFR inhibitor-naïve FGFR2-altered bile duct cancer.

A post hoc analysis suggests that patients who are PD-L1 high by Roche's SP142 test are more likely to live longer with Tecentriq than those deemed high expressers by Agilent's 22C3 test. 

The patient's personal and family history and genetic test results didn't indicate he was at high risk for colon cancer, yet he was having annual colonoscopies per a dermatologist's orders.